Skip to main content
Atrás
SHPMF logo

Shanghai Pharmaceuticals Holding Co., Ltd

Calidad de datos: 100%
Sobrecompra
SHPMF
OTC Healthcare Medical - Distribution
$1.46
$0.00 (0.00%)
Cap. Mercado: 8.46B
También listada como SHPMY OTC
Rango del Día
$1.46 $1.46
Rango de 52 Semanas
$1.46 $15.70
Volumen
100
Promedio 50D / 200D
$1.49 / $1.53
Cierre Anterior
$1.46

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 1.9 0.4
P/B 0.1 2.9
ROE % 6.5 3.8
Net Margin % 1.7 3.9
Rev Growth 5Y % 9.4 10.0
D/E 0.7 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 $1.50
$1.43 – $1.59
 320 B 1
FY2026 $1.36
$1.30 – $1.45
 300 B 1

Puntos Clave

Revenue grew 9.44% annually over 5 years — modest growth
Earnings grew 20.82% over the past year
Generating 3.43B in free cash flow
P/E of 1.86 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.69%
Capital efficient — spends only 0.87% of revenue on capex

Crecimiento

Revenue Growth (5Y)
9.44%
Revenue (1Y)5.75%
Earnings (1Y)20.82%
FCF Growth (3Y)29.02%

Calidad

Return on Equity
6.49%
ROIC5.11%
Net Margin1.65%
Op. Margin2.96%

Seguridad

Debt / Equity
0.67
Current Ratio1.36
Interest Coverage5.01

Valoración

P/E Ratio
1.86
P/B Ratio0.12
EV/EBITDA2.52
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 5.75% Revenue Growth (3Y) 8.93%
Earnings Growth (1Y) 20.82% Earnings Growth (3Y) -9.97%
Revenue Growth (5Y) 9.44% Earnings Growth (5Y) 0.31%
Profitability
Revenue (TTM) 275.25B Net Income (TTM) 4.55B
ROE 6.49% ROA 2.06%
Gross Margin 11.13% Operating Margin 2.96%
Net Margin 1.65% Free Cash Flow (TTM) 3.43B
ROIC 5.11% FCF Growth (3Y) 29.02%
Safety
Debt / Equity 0.67 Current Ratio 1.36
Interest Coverage 5.01 Dividend Yield 0.01%
Valuation
P/E Ratio 1.86 P/B Ratio 0.12
P/S Ratio 0.03 PEG Ratio 4.73
EV/EBITDA 2.52 Dividend Yield 0.01%
Market Cap 8.46B Enterprise Value 20.51B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 275.25B 260.30B 231.98B 215.82B 191.91B
Net Income 4.55B 3.77B 5.62B 5.09B 4.50B
EPS (Diluted) 1.23 1.02 1.61 1.79 1.58
Gross Profit 30.63B 31.33B 30.49B 28.54B 27.44B
Operating Income 8.14B 7.67B 9.01B 8.21B 7.18B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 221.21B 211.97B 198.13B 163.44B 149.19B
Total Liabilities 137.47B 131.65B 120.13B 104.37B 94.44B
Shareholders' Equity 71.68B 68.52B 67.06B 49.36B 45.35B
Total Debt 47.79B 42.90B 38.56B 31.69B 31.79B
Cash & Equivalents 35.74B 30.52B 27.40B 22.39B 22.30B
Current Assets 171.82B 162.43B 149.51B 116.49B 107.56B
Current Liabilities 126.04B 122.37B 110.69B 91.82B 88.13B

Puntuaciones de Estrategias

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#606 of 616
4

Actividad Reciente

Entró Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026